<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Triple-Negative Breast Cancer - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Triple-Negative Breast Cancer</span>
        </nav>

        <header class="page-header">
            <h1>Triple-Negative Breast Cancer</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0005494" target="_blank">
                        MONDO:0005494
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">breast carcinoma</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Triple-negative breast cancer (TNBC) is a molecularly-defined subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. TNBC represents approximately 10-20% of breast cancers and is clinically aggressive with higher rates of recurrence and visceral/brain metastases. TNBC is molecularly heterogeneous, encompassing several intrinsic subtypes including basal-like, mesenchymal, and immunomodulatory. Treatment relies on chemotherapy and increasingly immunotherapy, as hormonal and HER2-targeted therapies are ineffective by definition.
            </p>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Histopathology</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cancer</span>
                    
                    <span class="tag tag-classification">solid tumor</span>
                    
                </div>
            </div>
            
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">ICD-O Morphology</div>
                <div class="tag-list">
                    <span class="tag tag-classification">Adenocarcinoma</span>
                </div>
            </div>
            
            
            
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Basal-like TNBC</div>
                
                <div class="item-desc">The most common TNBC subtype (50-75%), characterized by expression of basal cytokeratins (CK5/6, CK14, CK17), EGFR expression, high proliferation, and frequent TP53 and BRCA1 mutations. Overlaps significantly with BRCA1-associated breast cancer.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21633166" target="_blank">PMID:21633166</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin."</div>
                
                
                <div class="evidence-explanation">The Lehmann et al. study identified basal-like subtypes (BL1 and BL2) with high cell cycle and DNA damage response gene expression, consistent with high proliferation and BRCA1 mutations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Mesenchymal TNBC</div>
                
                <div class="item-desc">Characterized by epithelial-mesenchymal transition features, enrichment in cell motility and differentiation pathways. May respond to PI3K/mTOR inhibition.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21633166" target="_blank">PMID:21633166</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor)."</div>
                
                
                <div class="evidence-explanation">The Lehmann et al. study confirmed mesenchymal subtypes are enriched for EMT and growth factor pathways, responding to PI3K/mTOR inhibition.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Luminal Androgen Receptor (LAR) TNBC</div>
                
                <div class="item-desc">Despite being ER/PR-negative, LAR tumors express androgen receptor and have luminal gene expression patterns. May benefit from androgen receptor-targeted therapy. Often have PIK3CA mutations.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21633166" target="_blank">PMID:21633166</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling. LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist)."</div>
                
                
                <div class="evidence-explanation">The Lehmann et al. study identified the LAR subtype characterized by AR signaling and sensitivity to AR antagonists.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Immunomodulatory TNBC</div>
                
                <div class="item-desc">Characterized by immune cell infiltration and immune checkpoint expression. Best responders to immune checkpoint inhibitor therapy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21633166" target="_blank">PMID:21633166</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cluster analysis identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype."</div>
                
                
                <div class="evidence-explanation">The Lehmann et al. study identified the immunomodulatory (IM) subtype as one of the six TNBC subtypes with unique gene expression profiles.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Loss of Hormone Receptor Signaling</div>
                
                <div class="item-desc">TNBC lacks expression of estrogen receptor alpha (ESR1) and progesterone receptor (PGR), eliminating the growth-promoting effects of estrogen signaling that drive most breast cancers. This absence removes a key therapeutic target but also indicates fundamentally different tumor biology.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        estrogen receptor signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030520" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚àÖ ABSENT
    </span>
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/41518487" target="_blank">PMID:41518487</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, remains clinically challenging due to the lack of effective targeted therapies."</div>
                
                
                <div class="evidence-explanation">This abstract defines TNBC by the absence of ER, PR, and HER2 expression, matching the mechanism described.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Alternative Oncogenic Pathways</div>
                
                <div class="item-desc">In the absence of hormone receptor signaling, TNBC is driven by alternative oncogenic pathways including EGFR signaling, PI3K-AKT-mTOR activation, and Wnt/beta-catenin signaling. Many TNBCs have TP53 mutations eliminating this tumor suppressor checkpoint.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        epidermal growth factor receptor signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007173" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        phosphatidylinositol 3-kinase signaling
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0014065" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">DNA Repair Deficiency</div>
                
                <div class="item-desc">A significant subset of TNBC (~20%) harbors germline or somatic BRCA1/2 mutations resulting in homologous recombination deficiency. This creates sensitivity to platinum chemotherapy and PARP inhibitors through synthetic lethality.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        homologous recombination
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0035825" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Aggressive Tumor Behavior</div>
                
                <div class="item-desc">TNBC is characterized by high proliferation rates, early metastasis (especially to viscera and brain), and shorter time to recurrence compared to other breast cancer subtypes. The aggressive biology reflects activation of multiple oncogenic pathways and loss of tumor suppressors.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35987766" target="_blank">PMID:35987766</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It accounts for 10-15% of incident breast cancers and carries the worst prognosis."</div>
                
                
                <div class="evidence-explanation">Abstract states TNBC carries the worst prognosis, supporting aggressive behavior.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ffedd5; color: #c2410c;">‚ú∂</div>
                <h2 class="card-title">Histopathology</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box histopathology-box">
                <div class="item-name">
                    Invasive Ductal Carcinoma
                    
                    <span class="histopathology-freq">VERY_FREQUENT</span>
                    
                </div>
                
                <div class="item-desc">Invasive ductal carcinoma is the most common type of breast cancer.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39806949" target="_blank">PMID:39806949</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Invasive ductal carcinoma (IDC) is the most common type of breast cancer,"</div>
                
                
                <div class="evidence-explanation">Abstract states that invasive ductal carcinoma is the most common breast cancer type.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (1):</strong>
                <ul>
                    
                    <li>Target &#39;Genomic Instability&#39; (from &#39;DNA Repair Deficiency&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Loss_of_Hormone_Receptor_Signaling[&#34;Loss of Hormone Receptor Signaling&#34;]
    Genomic_Instability[&#34;Genomic Instability&#34;]
    Alternative_Oncogenic_Pathways[&#34;Alternative Oncogenic Pathways&#34;]
    DNA_Repair_Deficiency[&#34;DNA Repair Deficiency&#34;]
    Aggressive_Tumor_Behavior[&#34;Aggressive Tumor Behavior&#34;]

    Loss_of_Hormone_Receptor_Signaling --&gt; Alternative_Oncogenic_Pathways
    Alternative_Oncogenic_Pathways --&gt; Aggressive_Tumor_Behavior
    DNA_Repair_Deficiency -.-&gt; Genomic_Instability

    style Loss_of_Hormone_Receptor_Signaling fill:#dbeafe
    style Genomic_Instability fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5
    style Alternative_Oncogenic_Pathways fill:#dbeafe
    style DNA_Repair_Deficiency fill:#dbeafe
    style Aggressive_Tumor_Behavior fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Breast Carcinoma
                    
                    <span class="phenotype-freq">OBLIGATE</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0003002" target="_blank">
                            HP:0003002
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Early Visceral Metastases
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Clinical</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002664" target="_blank">
                            HP:0002664
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Triple-Negative Phenotype
                    
                    <span class="phenotype-freq">OBLIGATE</span>
                    
                    
                    <span class="phenotype-category">Molecular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002664" target="_blank">
                            HP:0002664
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35987766" target="_blank">PMID:35987766</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification."</div>
                
                
                <div class="evidence-explanation">Abstract defines TNBC by lack of ER/PR and HER2, matching the diagnostic phenotype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TP53
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Mutations)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Somatic</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31045815" target="_blank">PMID:31045815</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"TP53 gene is mutated in approximately 80% of triple-negative breast cancer (TNBC)."</div>
                
                
                <div class="evidence-explanation">Abstract reports TP53 mutation frequency in TNBC, supporting this genetic association.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BRCA1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Germline and Somatic Mutations)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Somatic</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PIK3CA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Mutations)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Somatic</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Neoadjuvant Chemotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Standard treatment includes anthracycline and taxane-based regimens given before surgery. Pathologic complete response (pCR) rates are higher in TNBC than other subtypes and strongly predict long-term outcomes.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32046998" target="_blank">PMID:32046998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with a pCR after NAT had significantly better EFS (HR = 0.31; 95% PI, 0.24-0.39), particularly for triple-negative (HR = 0.18; 95% PI, 0.10-0.31) and HER2+ (HR = 0.32; 95% PI, 0.21-0.47) disease."</div>
                
                
                <div class="evidence-explanation">Meta-analysis confirms that achieving pCR after neoadjuvant therapy is strongly associated with improved event-free survival, particularly for TNBC.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Pembrolizumab Plus Chemotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab in the neoadjuvant/adjuvant setting regardless of PD-L1 status.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32101663" target="_blank">PMID:32101663</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy."</div>
                
                
                <div class="evidence-explanation">KEYNOTE-522 demonstrated significantly higher pCR rates with pembrolizumab plus chemotherapy versus chemotherapy alone in early TNBC.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    PARP Inhibitors
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Olaparib and talazoparib are approved for germline BRCA-mutated metastatic TNBC. They exploit synthetic lethality in HRD-positive tumors unable to repair DNA double-strand breaks.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33475295" target="_blank">PMID:33475295</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1 and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer."</div>
                
                
                <div class="evidence-explanation">Review confirms PARP inhibitors cause synthetic lethality in BRCA-mutated breast cancers and are standard of care for metastatic disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Sacituzumab Govitecan
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved for previously treated metastatic TNBC with significant survival benefit demonstrated in ASCENT trial.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33882206" target="_blank">PMID:33882206</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer."</div>
                
                
                <div class="evidence-explanation">ASCENT trial demonstrated significant PFS and OS benefit with sacituzumab govitecan versus chemotherapy in metastatic TNBC.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Platinum Chemotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Carboplatin improves pCR rates in neoadjuvant therapy, particularly in BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21633166" target="_blank">PMID:21633166</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin."</div>
                
                
                <div class="evidence-explanation">Basal-like TNBC subtypes with DNA damage response gene expression preferentially respond to platinum chemotherapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Hormone Receptor and HER2 Testing
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    BRCA1/2 Testing
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Triple-Negative Breast Cancer
description: &gt;-
  Triple-negative breast cancer (TNBC) is a molecularly-defined subtype of breast
  cancer characterized by the absence of estrogen receptor (ER), progesterone
  receptor (PR), and HER2 expression. TNBC represents approximately 10-20% of
  breast cancers and is clinically aggressive with higher rates of recurrence
  and visceral/brain metastases. TNBC is molecularly heterogeneous, encompassing
  several intrinsic subtypes including basal-like, mesenchymal, and
  immunomodulatory. Treatment relies on chemotherapy and increasingly immunotherapy,
  as hormonal and HER2-targeted therapies are ineffective by definition.
categories:
- Molecularly-Defined Cancer
- Breast Cancer Subtype
- Solid Tumor
parents:
- breast carcinoma
has_subtypes:
- name: Basal-like TNBC
  description: &gt;-
    The most common TNBC subtype (50-75%), characterized by expression of basal
    cytokeratins (CK5/6, CK14, CK17), EGFR expression, high proliferation, and
    frequent TP53 and BRCA1 mutations. Overlaps significantly with BRCA1-associated
    breast cancer.
  evidence:
  - reference: PMID:21633166
    supports: SUPPORT
    snippet: &gt;-
      BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage
      response genes, and representative cell lines preferentially responded to
      cisplatin.
    explanation: &gt;-
      The Lehmann et al. study identified basal-like subtypes (BL1 and BL2) with
      high cell cycle and DNA damage response gene expression, consistent with
      high proliferation and BRCA1 mutations.
- name: Mesenchymal TNBC
  description: &gt;-
    Characterized by epithelial-mesenchymal transition features, enrichment in
    cell motility and differentiation pathways. May respond to PI3K/mTOR inhibition.
  evidence:
  - reference: PMID:21633166
    supports: SUPPORT
    snippet: &gt;-
      M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition,
      and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR
      inhibitor) and dasatinib (an abl/src inhibitor).
    explanation: &gt;-
      The Lehmann et al. study confirmed mesenchymal subtypes are enriched for EMT
      and growth factor pathways, responding to PI3K/mTOR inhibition.
- name: Luminal Androgen Receptor (LAR) TNBC
  description: &gt;-
    Despite being ER/PR-negative, LAR tumors express androgen receptor and have
    luminal gene expression patterns. May benefit from androgen receptor-targeted
    therapy. Often have PIK3CA mutations.
  evidence:
  - reference: PMID:21633166
    supports: SUPPORT
    snippet: &gt;-
      The LAR subtype includes patients with decreased relapse-free survival and
      was characterized by androgen receptor (AR) signaling. LAR cell lines were
      uniquely sensitive to bicalutamide (an AR antagonist).
    explanation: &gt;-
      The Lehmann et al. study identified the LAR subtype characterized by AR
      signaling and sensitivity to AR antagonists.
- name: Immunomodulatory TNBC
  description: &gt;-
    Characterized by immune cell infiltration and immune checkpoint expression.
    Best responders to immune checkpoint inhibitor therapy.
  evidence:
  - reference: PMID:21633166
    supports: SUPPORT
    snippet: &gt;-
      Cluster analysis identified 6 TNBC subtypes displaying unique GE and
      ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM),
      a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen
      receptor (LAR) subtype.
    explanation: &gt;-
      The Lehmann et al. study identified the immunomodulatory (IM) subtype as
      one of the six TNBC subtypes with unique gene expression profiles.
pathophysiology:
- name: Loss of Hormone Receptor Signaling
  description: &gt;-
    TNBC lacks expression of estrogen receptor alpha (ESR1) and progesterone
    receptor (PGR), eliminating the growth-promoting effects of estrogen signaling
    that drive most breast cancers. This absence removes a key therapeutic target
    but also indicates fundamentally different tumor biology.
  evidence:
  - reference: PMID:41518487
    supports: SUPPORT
    snippet: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone 
      receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, remains clinically challenging due 
      to the lack of effective targeted therapies.
    explanation: This abstract defines TNBC by the absence of ER, PR, and HER2 expression, matching the mechanism 
      described.
  biological_processes:
  - preferred_term: estrogen receptor signaling pathway
    modifier: ABSENT
    term:
      id: GO:0030520
      label: intracellular estrogen receptor signaling pathway
  downstream:
  - target: Alternative Oncogenic Pathways
    description: Other signaling pathways drive proliferation in absence of ER
- name: Alternative Oncogenic Pathways
  description: &gt;-
    In the absence of hormone receptor signaling, TNBC is driven by alternative
    oncogenic pathways including EGFR signaling, PI3K-AKT-mTOR activation, and
    Wnt/beta-catenin signaling. Many TNBCs have TP53 mutations eliminating this
    tumor suppressor checkpoint.
  biological_processes:
  - preferred_term: epidermal growth factor receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007173
      label: epidermal growth factor receptor signaling pathway
  - preferred_term: phosphatidylinositol 3-kinase signaling
    modifier: INCREASED
    term:
      id: GO:0014065
      label: phosphatidylinositol 3-kinase signaling
  downstream:
  - target: Aggressive Tumor Behavior
    description: Multiple activated pathways drive aggressive phenotype
- name: DNA Repair Deficiency
  description: &gt;-
    A significant subset of TNBC (~20%) harbors germline or somatic BRCA1/2
    mutations resulting in homologous recombination deficiency. This creates
    sensitivity to platinum chemotherapy and PARP inhibitors through synthetic
    lethality.
  biological_processes:
  - preferred_term: homologous recombination
    modifier: DECREASED
    term:
      id: GO:0035825
      label: homologous recombination
  downstream:
  - target: Genomic Instability
    description: DNA repair defects lead to mutation accumulation
- name: Aggressive Tumor Behavior
  description: &gt;-
    TNBC is characterized by high proliferation rates, early metastasis (especially
    to viscera and brain), and shorter time to recurrence compared to other breast
    cancer subtypes. The aggressive biology reflects activation of multiple
    oncogenic pathways and loss of tumor suppressors.
  evidence:
  - reference: PMID:35987766
    supports: SUPPORT
    snippet: &#34;It accounts for 10-15% of incident breast cancers and carries the worst prognosis.&#34;
    explanation: &#34;Abstract states TNBC carries the worst prognosis, supporting aggressive behavior.&#34;
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
histopathology:
- name: Invasive Ductal Carcinoma
  finding_term:
    preferred_term: Invasive Breast Carcinoma of No Special Type
    term:
      id: NCIT:C4194
      label: Invasive Breast Carcinoma of No Special Type
  frequency: VERY_FREQUENT
  description: Invasive ductal carcinoma is the most common type of breast cancer.
  evidence:
  - reference: PMID:39806949
    supports: SUPPORT
    snippet: &#34;Invasive ductal carcinoma (IDC) is the most common type of breast cancer,&#34;
    explanation: Abstract states that invasive ductal carcinoma is the most common breast cancer type.

phenotypes:
- category: Neoplastic
  name: Breast Carcinoma
  frequency: OBLIGATE
  diagnostic: true
  description: &gt;-
    Triple-negative breast cancers are typically high-grade invasive ductal
    carcinomas with high mitotic rates. Medullary and metaplastic histologies
    are enriched in the TNBC population.
  phenotype_term:
    preferred_term: Breast carcinoma
    term:
      id: HP:0003002
      label: Breast carcinoma
- category: Clinical
  name: Early Visceral Metastases
  frequency: FREQUENT
  description: &gt;-
    TNBC has a predilection for visceral metastases (lung, liver) and brain
    metastases, occurring earlier and more frequently than in ER+ breast cancer.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
- category: Molecular
  name: Triple-Negative Phenotype
  frequency: OBLIGATE
  diagnostic: true
  description: &gt;-
    Defining feature is absence of ER (&lt;1%), PR (&lt;1%), and HER2 (IHC 0-1+ or
    FISH non-amplified). This is a diagnosis of exclusion from other breast
    cancer subtypes.
  evidence:
  - reference: PMID:35987766
    supports: SUPPORT
    snippet: &#34;Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification.&#34;
    explanation: &#34;Abstract defines TNBC by lack of ER/PR and HER2, matching the diagnostic phenotype.&#34;
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
biochemical:
- name: Hormone Receptor and HER2 Testing
  notes: &gt;-
    Diagnosis requires testing for ER, PR (by IHC), and HER2 (by IHC and/or FISH).
    Triple-negative is defined as ER &lt;1%, PR &lt;1%, and HER2 0-1+ or non-amplified.
    PD-L1 testing (CPS or SP142) is recommended for treatment selection.
- name: BRCA1/2 Testing
  notes: &gt;-
    Germline BRCA1/2 testing is recommended for all TNBC patients given high
    prevalence of mutations (~15-20%) and therapeutic implications (PARP inhibitors).
    Somatic testing may identify additional HRD-positive tumors.
genetic:
- name: TP53
  association: Somatic Mutations
  inheritance:
  - name: Somatic
  notes: &gt;-
    TP53 mutations occur in approximately 80% of TNBC, the highest rate among
    breast cancer subtypes. Mutations are typically missense in the DNA-binding
    domain or truncating mutations.
  evidence:
  - reference: PMID:31045815
    supports: SUPPORT
    snippet: &#34;TP53 gene is mutated in approximately 80% of triple-negative breast cancer (TNBC).&#34;
    explanation: &#34;Abstract reports TP53 mutation frequency in TNBC, supporting this genetic association.&#34;
- name: BRCA1
  association: Germline and Somatic Mutations
  inheritance:
  - name: Autosomal Dominant
  - name: Somatic
  notes: &gt;-
    BRCA1 germline mutations are enriched in TNBC, occurring in 10-15% of cases.
    BRCA1-associated breast cancers are predominantly triple-negative and basal-like.
    Somatic BRCA1 mutations and promoter methylation also occur.
- name: PIK3CA
  association: Somatic Mutations
  inheritance:
  - name: Somatic
  notes: &gt;-
    PIK3CA mutations occur in approximately 10-20% of TNBC, particularly in the
    LAR subtype. May identify patients who benefit from PI3K inhibitors.
treatments:
- name: Neoadjuvant Chemotherapy
  description: &gt;-
    Standard treatment includes anthracycline and taxane-based regimens given
    before surgery. Pathologic complete response (pCR) rates are higher in TNBC
    than other subtypes and strongly predict long-term outcomes.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
  evidence:
  - reference: PMID:32046998
    supports: SUPPORT
    snippet: &gt;-
      Patients with a pCR after NAT had significantly better EFS (HR = 0.31; 95%
      PI, 0.24-0.39), particularly for triple-negative (HR = 0.18; 95% PI,
      0.10-0.31) and HER2+ (HR = 0.32; 95% PI, 0.21-0.47) disease.
    explanation: &gt;-
      Meta-analysis confirms that achieving pCR after neoadjuvant therapy is
      strongly associated with improved event-free survival, particularly for TNBC.
- name: Pembrolizumab Plus Chemotherapy
  description: &gt;-
    PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes
    in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab
    in the neoadjuvant/adjuvant setting regardless of PD-L1 status.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:32101663
    supports: SUPPORT
    snippet: &gt;-
      Among patients with early triple-negative breast cancer, the percentage
      with a pathological complete response was significantly higher among those
      who received pembrolizumab plus neoadjuvant chemotherapy than among those
      who received placebo plus neoadjuvant chemotherapy.
    explanation: &gt;-
      KEYNOTE-522 demonstrated significantly higher pCR rates with pembrolizumab
      plus chemotherapy versus chemotherapy alone in early TNBC.
- name: PARP Inhibitors
  description: &gt;-
    Olaparib and talazoparib are approved for germline BRCA-mutated metastatic
    TNBC. They exploit synthetic lethality in HRD-positive tumors unable to
    repair DNA double-strand breaks.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33475295
    supports: SUPPORT
    snippet: &gt;-
      PARP inhibition causes synthetic lethality in breast cancers associated
      with germline BRCA1 and BRCA2 mutations and is routinely used in clinical
      practice for metastatic breast cancer.
    explanation: &gt;-
      Review confirms PARP inhibitors cause synthetic lethality in BRCA-mutated
      breast cancers and are standard of care for metastatic disease.
- name: Sacituzumab Govitecan
  description: &gt;-
    Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved
    for previously treated metastatic TNBC with significant survival benefit
    demonstrated in ASCENT trial.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33882206
    supports: SUPPORT
    snippet: &gt;-
      Progression-free and overall survival were significantly longer with
      sacituzumab govitecan than with single-agent chemotherapy among patients
      with metastatic triple-negative breast cancer.
    explanation: &gt;-
      ASCENT trial demonstrated significant PFS and OS benefit with sacituzumab
      govitecan versus chemotherapy in metastatic TNBC.
- name: Platinum Chemotherapy
  description: &gt;-
    Carboplatin improves pCR rates in neoadjuvant therapy, particularly in
    BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
  evidence:
  - reference: PMID:21633166
    supports: SUPPORT
    snippet: &gt;-
      BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage
      response genes, and representative cell lines preferentially responded to
      cisplatin.
    explanation: &gt;-
      Basal-like TNBC subtypes with DNA damage response gene expression
      preferentially respond to platinum chemotherapy.
disease_term:
  preferred_term: triple-negative breast carcinoma
  term:
    id: MONDO:0005494
    label: triple-negative breast carcinoma

classifications:
  icdo_morphology:
    classification_value: Adenocarcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Triple_Negative_Breast_Cancer.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>